Novo starts a phase 3 trial of lower daily doses of the Wegovy pill

A newly registered trial will test how much weight two lower daily doses of the Wegovy pill produce and track their side effects.

The study is registered on ClinicalTrials.gov as NCT07770841 and is known as OASIS 5. Its official title is a study of efficacy and safety of once-daily oral semaglutide in adults with overweight or obesity. Novo Nordisk A/S is the sponsor. Enrollment opened August 12, 2026, and the registry lists primary completion for February 22, 2028 and final completion for April 11, 2028.

About 450 adults will be assigned by chance to one of two lower doses or a placebo, an inactive comparison treatment. Everyone will also receive guidance on diet and physical activity. The main result is the percent change in body weight from the start of the study to week 60.

Researchers will count how many participants lose at least 5%, 10%, and 15% of their starting weight. Other measures include waist size, blood pressure, fasting blood sugar, and HbA1c, which reflects average blood sugar over about three months.

Researchers will also track an inflammation marker named hsCRP and blood fats such as cholesterol and triglycerides. Safety follow-up continues through week 67. The registry lists 60 sites across ten countries.

Participants must be at least 18 and have a body mass index of 30 or higher. Adults with a BMI of at least 27 also qualify with a weight-related health condition. They must also have made an earlier unsuccessful weight-loss attempt.

The registry excludes people with an HbA1c of 6.5% or higher and people with recent large weight changes. It also excludes anyone who previously used a GLP-1 medicine. That last rule limits how well the results apply to experienced GLP-1 users.

The registry does not identify the two lower doses. Novo also declined to disclose them to the Wall Street Journal and BioSpace. The approved maintenance dose of the Wegovy pill is 25 mg once daily. Patients reach it after about three months of gradual dose increases, a process called dose escalation.

The trial tests lower daily doses over 60 weeks

The key question is how much weight loss the two lower daily doses produce and what side effects occur. Nausea and other digestive side effects often occur at higher doses and while the dose is increasing.

A positive result can give prescribers evidence for another daily dosing option. Lower doses also use less active ingredient, but OASIS 5 is not designed to determine price or medicine supply.

The trial is enrolling at 60 sites in ten countries. Contact information for participating sites appears on the public ClinicalTrials.gov record.

OASIS 5 has no results yet

This trial has just started. OASIS 5 has no results on weight loss or safety. The registry lists February 2028 for the main completion date.

The dose levels remain undisclosed, so “lower” has no public milligram value. Novo explained its rationale through business reporting rather than a peer-reviewed paper or regulatory filing. Registry dates, site counts, and enrollment targets can also change.

The trial excludes anyone who previously used a GLP-1 medicine. It therefore will not answer whether current users can safely step down to a lower maintenance dose. The study does not show that the approved 25 mg dose is wrong.